BCACP Anticoagulation Management 2

Question 1

Which DOAC has the lowest proportion of renal elimination (~27%), making it most suitable in patients with chronic kidney disease?

Accepted Answer

Apixaban

Answer

Dabigatran

Answer

Rivaroxaban

Answer

Edoxaban

Question 2

Idarucizumab (Praxbind) is the FDA-approved specific reversal agent for which anticoagulant?

Accepted Answer

Dabigatran

Answer

Rivaroxaban

Answer

Apixaban

Answer

Edoxaban

Question 3

Andexanet alfa (Andexxa) is FDA-approved for reversal of which anticoagulants in life-threatening bleeding?

Accepted Answer

Rivaroxaban and apixaban

Answer

Dabigatran and argatroban

Answer

Warfarin and fondaparinux

Answer

Unfractionated heparin and enoxaparin

Question 4

According to AHA/ACC guidelines, oral anticoagulation is RECOMMENDED (not merely considered) for males with nonvalvular atrial fibrillation when their CHA2DS2-VASc score reaches:

Accepted Answer

2 or greater

Answer

1 or greater

Answer

3 or greater

Answer

4 or greater

Question 5

Which anticoagulant regimen is now preferred over LMWH for cancer-associated thrombosis in patients without high gastrointestinal or genitourinary bleeding risk?

Accepted Answer

Apixaban or rivaroxaban (direct oral anticoagulants)

Answer

Warfarin with target INR 2.0–3.0

Answer

Aspirin 81 mg plus clopidogrel 75 mg

Answer

Fondaparinux subcutaneous injection

Question 6

A patient taking apixaban requires emergent surgery within 8 hours after a serious fall. Which is the most appropriate reversal strategy?

Accepted Answer

Andexanet alfa per weight-based dosing protocol

Answer

Vitamin K 10 mg IV infusion

Answer

Protamine sulfate IV bolus

Answer

Idarucizumab 5 g IV

Question 7

All DOACs are contraindicated for stroke prevention in atrial fibrillation in patients with which of the following conditions?

Accepted Answer

Mechanical prosthetic heart valve

Answer

Age greater than 75 years

Answer

CrCl between 40 and 50 mL/min

Answer

Controlled hypertension on two medications